• Forum
  • Stock Markets
    • MarketsLive prices, indices, and market performance
    • Stock CalendarUpcoming earnings, listings, and corporate events
    • Dividends CalendarFuture and past dividends
  • Companies
    • CompaniesBrowse and filter the full list of listed companies
    • DiscoveryInspiration for your next investment
    • IPOsNew listings and upcoming public offerings
    • AGM InvitationsAnnual general meeting dates and shareholder info
  • Stock Research
    • ResearchExpert stock analysis and recommendations
    • ArticlesNews, insights, and market commentary
    • inderesTVVideo hub for stock research, analysis, and expert commentary
    • TranscriptsFull text records of earnings calls and investor meetings
    • Stock ComparisonCompare financials and performance across multiple stocks
Find us on social media
  • Inderes Forum
  • Youtube
  • Facebook
  • X (Twitter)
Get in touch
  • info@hcandersencapital.dk
  • Bredgade 23B, 2. sal
    1260 København K
Inderes
  • About us
  • Our team
  • Careers
  • Inderes as an investment
  • Services for listed companies
Our platform
  • FAQ
  • Terms of service
  • Privacy policy
  • Disclaimer

Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.

Kancera

Less than 1K followers
Overview
Investor consensus
All
Webcasts
Press releases
ShowingAll content types

Press release3/31/2026, 6:00 AM

Novakand Pharma to hold Extraordinary General Meeting to decide on future business direction – Comments from the board of directors

Kancera
Press release3/2/2026, 6:00 AM

Novakand’s Board of Directors proposes new business direction and relisting to be presented at Extraordinary General Meeting

Kancera
Press release2/25/2026, 3:45 PM

The board evaluates Novakand Pharma’s options after the decision not to execute the planned reverse take over of SVF Vaccines

Kancera

Join Inderes community

Don't miss out - create an account and get all the possible benefits

Inderes account
Followings and notifications on followed companies
Analyst comments and recommendations
Stock comparison tool & other popular tools
Create account
Press release2/12/2026, 4:45 PM

Novakand Pharma applies for Nasdaq’s approval of continued listing of the combined company post a completed reverse takeover with SVF Vaccines

Kancera
Press release2/6/2026, 7:00 AM

Novakand Pharma enters into share purchase agreement with SVF Vaccines regarding a reverse takeover

Kancera
Regulatory press release12/22/2025, 7:00 AM

Novakand Pharma enters Letter of Intent with SVF Vaccines regarding a reverse takeover

Kancera
Regulatory press release11/21/2025, 7:00 AM

Interim Report Third Quarter 2025, July 1 – September 30 Novakand Pharma AB (publ.), org.no. 556806-8851

Kancera
Press release10/9/2025, 7:00 AM

Novakand Pharma provides an update on the ongoing reverse take over process

Kancera
Regulatory press release9/23/2025, 1:00 PM

Peter Selin resigns as CEO of Novakand Pharma in mutual agreement with the board

Kancera
Regulatory press release9/22/2025, 2:00 PM

Kancera AB changes name to Novakand Pharma AB

Kancera
Regulatory press release9/18/2025, 4:00 PM

Kancera initiates process to seek stakeholders for a reverse take over

Kancera
Regulatory press release8/28/2025, 6:00 AM

Interim Report First Quarter 2025, April 1 – June 30 Kancera AB (publ.), org.no. 556806-8851

Kancera
Regulatory press release8/12/2025, 6:00 AM

Kancera terminates letter of intent with Recardio

Kancera
Press release6/16/2025, 6:30 AM

Kancera announces rugocrixan and fosrugocrixan as the International Non-proprietary Names for KAND567 and KAN145

Kancera
Regulatory press release6/13/2025, 6:00 AM

Kancera reports positive top-line results from the KANDOVA study

Kancera
Regulatory press release6/5/2025, 6:00 AM

Kancera reports positive outcome of pre-IND meeting with FDA

Kancera
Press release5/27/2025, 6:39 AM

Redeye: Kancera Q1 - Continued efforts with Recardio

Kancera
Regulatory press release5/23/2025, 6:00 AM

Interim Report First Quarter 2025, January 1 – March 31 Kancera AB (publ.), org.no. 556806-8851

Kancera
Press release5/20/2025, 6:30 AM

Kancera provides an update on the collaboration with Recardio Inc. and the company’s clinical development program

Kancera
Press release4/8/2025, 6:00 AM

Kancera reports Last Patient Last Visit in the KANDOVA study

Kancera